Results 101 to 110 of about 29,485 (291)

The T‐Cell Response Mechanism in Human Papillomavirus‐Associated Cervical Cancer and New Strategies for Immunotherapy

open access: yesiNew Medicine, EarlyView.
ABSTRACT Human papillomavirus (HPV) is a double‐stranded DNA virus that infects human skin and mucosal tissues exclusively. The German scientist Harald zur Hausen was awarded the 2008 Nobel Prize in Physiology or Medicine for his discovery of the link between HPV infection and cervical cancer.
Fang Zhu   +5 more
wiley   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

open access: yesiNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid   +4 more
wiley   +1 more source

Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies

open access: yes, 2016
With the development of molecular cloning technology and the deep understanding of antibody engineering, there are diverse bispecific antibody formats from which to choose to pursue the optimal biological activity and clinical purpose.
Fa Yang, Weijun Qin, Weihong Wen
core   +1 more source

Potent monoclonal antibodies against multidrug‐resistant hypervirulent Klebsiella pneumoniae

open access: yesInterdisciplinary Medicine, EarlyView.
A novel immunization strategy using a low‐virulence, multidrug‐resistant strain yields synergistic monoclonal antibodies against hypervirulent Klebsiella pneumoniae. These antibodies provide cross‐serotype protection through a dual‐mechanism of pathogen clearance and immunomodulation, offering a promising non‐antibiotic therapeutic for resistant ...
Yushan Jiang   +10 more
wiley   +1 more source

Development of Bispecific Antibody Targeting Human IL-17A and IL-6

open access: yesAntibodies
Background/Objectives: Antibodies are a rapidly expanding field in drug discovery, but their monospecificity limits therapeutic applications, particularly in complex inflammatory diseases.
Beata Pamuła   +13 more
doaj   +1 more source

Intelligent design of artificial biocatalyst for biomedical diseases

open access: yesJournal of Intelligent Medicine, EarlyView.
This review summarizes recent advances in the intelligent design of artificial biocatalysts for biomedical diseases. By leveraging tailored design strategies, including environment‐responsive engineering and rational/artificial intelligence‐aided optimization, these biocatalysts enable precise modulation of pathological microenvironments and targeted ...
Lijie Zhang   +3 more
wiley   +1 more source

Recent Advances (2023–2025) of Capillary Electrophoresis‐Mass Spectrometry (CE‐MS) for Top‐Down Proteomics

open access: yesMass Spectrometry Reviews, EarlyView.
ABSTRACT Top‐down proteomics (TDP) characterizes proteoforms in cells, tissues, and biofluids, in discovery mode and on a global scale, requiring analytical tools with high peak capacity for proteoform separation and high sensitivity for proteoform detection, given the extremely high proteoform complexity and wide proteoform concentration dynamic range.
Guijie Zhu   +5 more
wiley   +1 more source

Fatigue in Myasthenia Gravis: Recent Advances and Emerging Concepts

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Fatigue is a common, often disabling symptom in myasthenia gravis (MG), distinct from muscle fatigability, and strongly associated with reduced quality of life. This narrative review examines current evidence on fatigue in MG, its patient impact, and future research directions. Earlier studies, mostly small and heterogeneous, reported a highly
Yvonne J. M. Campman   +3 more
wiley   +1 more source

Bispecific Nanosystems Enable Multieffector Immune Cell Retargeting for Hematologic Malignancy Therapy

open access: yesAdvanced Science
B‐cell lymphomas are hematologic malignancies characterized by poor prognoses. Immunotherapy has revolutionized B‐cell lymphoma treatment by harnessing immune effector cells, but current therapeutic strategies face limitations: suboptimal ...
Yefeng Shen   +12 more
doaj   +1 more source

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma

open access: yes, 2020
B-cell maturation antigen (BCMA)-targeting bispecific antibodies and bispecific T-cell engagers (BiTEs) redirect T-cells to BCMA-expressing multiple myeloma (MM) cells. These MM cells are subsequently eliminated via various mechanisms of action including
Verkleij, Christie P.M.   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy